Listing of Included Studies

Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50(2):398-402.

Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120 (Pt 11):2059-69.

Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988;15(1):15-9.

Bastianello S, Pozzilli C, D'Andrea F, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994;21(3):266-70.

Beatty WW, Blanco CR, Wilbanks SL, et al. Demographic, clinical and cognitive characteristics of multiple sclerosis patients who continue to work. J Neurol Rehab 1995;9:167-73.

Beukelman DR, Kraft GH, Freal J. Expressive communication disorders in persons with multiple sclerosis: a survey. Arch Phys Med Rehab 1985;66(10):675-7.

Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New Engl J Med 1987;317(7):408-14.

Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991;41(4):533-9.

Brar SP, Smith MB, Nelson LM, et al. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehab 1991;72(3):186-9.

Brex PA, Miszkiel KA, O'Riordan JI, et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psych 2001;70(3):390-3.

British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2(8604):179-83.

Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part I: Cost of illness. Can J Neurol Sci 1998a;25(1):23-30.

Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: Quality of life. Can J Neurol Sci 1998b;25(1):31-8.

Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337(8739):441-6.

Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987;14(3):273-8.

Cartlidge NE, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974;23(1):17-24.

CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002;59(7):998-1005.

Chapman J, Sylantiev C, Nisipeanu P, et al. Preliminary observations on APOE epsilon4 allele and progression of disability in multiple sclerosis. Arch Neurol 1999;56(12):1484-7.

Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59(5):679-87.

Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989;46(6):676-80.

Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357(9268):1576-82.

Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999a;122 (Pt 4):641-7.

Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999b;122 (Pt 4):625-39.

Crawford JD, McIvor GP. Group psychotherapy: benefits in multiple sclerosis. Arch Phys Med Rehab 1985;66(12):810-3.

Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot

study.[erratum appears in J Neurol Neurosurg Psychiatry 1994 Apr;57(4):528]. J Neurol Neurosurg Psych 1993;56(11):1217-8.

Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehab 2000;81(2):164-9.

Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psych 2002;73(2):141-7.

Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52(1):47-53.

De Castro S, Cartoni D, Millefiorini E, et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995;35(6):627-32.

Dyck I, Jongbloed L. Women with multiple sclerosis and employment issues: a focus on social and institutional environments. Can J Occup Therapy 2000;67(5):337-46.

Edgley K, Sullivan M, Dehoux E. A survey of multiple sclerosis: determinants of employment status. Can J Rehabil 1991;4:127-32.

European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352(9139):1491-7.

Eyssette M, Rohmer F, Serratrice G, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opinion 1988;10(10):699-708.

Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997a;349(9052):589-93.

Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. Mult Scler 1997b;3(2):137-41.

Feldman RG, Kelly-Hayes M, Conomy JP, et al. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology 1978;28(11):1094-8.

Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44(4):635-41.

Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000;48(6):885-92.

Foley FW, Bedell JR, LaRocca NG, et al. Efficacy of stress-inoculation training in coping with multiple sclerosis. J Consult Clin Psychol 1987;55(6):919-22.

Ford HL, Johnson MH, Rigby AS. Variation between observers in classifying multiple sclerosis. J Neurol Neurosurg Psych 1996;61(4):418.

Francabandera FL, Holland NJ, Wiesel-Levison P, et al. Multiple sclerosis rehabilitation: inpatient vs. outpatient. Rehab Nurs 1988;13(5):251-3.

Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehab 1984;65(3):135-8.

Fredrikson S. Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurol Scand 1996;94(1):31-4.

Freeman JA, Langdon DW, Hobart JC, et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997;42(2):236-44.

Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 2001;57(10):1870-5.

From A, Heltberg A. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975;51(2):158-66.

Fuhr P, Borggrefe-Chappuis A, Schindler C, et al. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001;124(Pt 11):2162-8.

Gambi D, Rossini PM, Calenda G, et al. Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: a double-blind, crossover study in comparison with placebo. Curr Therapeutic Res 1983;33:835-40.

Geisler MW, Sliwinski M, Coyle PK, et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996;53(2):185-8.

Genevie L, Kallos JE, Struening EL. Job retention among people with multiple sclerosis. J Neurol Rehab 1987;1:131-5.

Ghezzi A, DiFalco MLC, et al. Clinical controlled randomized trial of azathioprine in multiple sclerosis. In: Gonsette RE, Delmotte P, eds. *Recent Advances in Multiple Sclerosis Therapy*. Amsterdam: Elsevier, 1989.

Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999;246(9):770-5.

Gillson G, Richard TL, Smith RB, et al. A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis. Mult Scler 2002;8(1):30-5.

Goodkin DE, Bailly RC, Teetzen ML, et al. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41(1):20-5.

Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46(10):1107-12.

Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37(1):30-40.

Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000;6(2):91-8.

Grønning M, Hannisdal E, Mellgren SI. Multivariate analyses of factors associated with unemployment in people with multiple sclerosis. J Neurol Neurosurg Psych 1990;53(5):388-90.

Gulick EE, Yam M, Touw MM. Work performance by persons with multiple sclerosis: conditions that impede or enable the performance of work. Internat J Nurs Stud 1989;26(4):301-11.

Hammond SR, McLeod JG, Macaskill P, et al. Multiple sclerosis in Australia: socioeconomic factors. J Neurol Neurosurg Psych 1996;61(3):311-3.

Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360(9350):2018-25.

Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. New Engl J Med 1983;308(4):173-80.

Hauser SL, Doolittle TH, Lopez-Bresnahan M, et al. An antispasticity effect of threonine in multiple sclerosis. Arch Neurol 1992;49(9):923-6.

Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psych 1983;46(9):854-5.

Hoogstraten MC, van der Ploeg RJ, vd Burg W, et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand 1988;77(3):224-30.

Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psych 1998;65(5):778-80.

Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psych 2000;68(6):707-12.

IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43(4):655-61.

IFNB Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45(7):1277-85.

IFNB Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47(4):889-94.

Jacobs L, Rudick R, Simon J. Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics. J Neuroimmunol 2000;107(2):167-73.

Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [erratum appears in Ann Neurol 1996 Sep;40(3):480]. Ann Neurol 1996;39(3):285-94.

Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999;5(5):369-76.

Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50(3):701-8.

Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III

multicenter, double-blind, placebo-controlled trial. 1995 [classical article]. Neurology 2001;57(12 Suppl 5):S16-24.

Jongbloed L. Factors influencing employment status of women with multiple sclerosis. Can J Rehab 1996;9(213-22).

Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001;57(11):1969-75.

Khatri BO, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985;35(3):312-9.

Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58(9):1404-7.

Kinn AC, Larsson PO. Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. Scand J Urol Nephrol 1990;24(2):109-12.

Kornblith AB, La Rocca NG, Baum HM. Employment in individuals with multiple sclerosis. Internat J Rehab Res 1986;9(2):155-65.

Koziol JA, Wagner S, Sobel DF, et al. Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis. Am J Neuroradiol 2001;22(2):284-91.

Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45(11):1956-61.

Larcombe NA, Wilson PH. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. Brit J Psych 1984;145:366-71.

LaRocca N, Kalb R, Kendall P, et al. The role of disease and demographic factors in the employment of patients with multiple sclerosis. Arch Neurol 1982;39(4):256.

Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60(1):44-51.

Lee A, Patterson V. A double-blind study of L-threonine in patients with spinal spasticity. Acta Neurol Scand 1993;88(5):334-8.

Levine IM, Jossmann PB, DeAngelis V. Liorseal, a new muscle relaxant in the treatment of spasticity--a double-blind quantitative evaluation. Dis Nerv System 1977;38(12):1011-5.

Lincoln NB, Dent A, Harding J, et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psych 2002;72(1):93-8.

Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psych 1999;67(4):451-6.

Liu C, Blumhardt LD. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group. J Neurol Sci 2000;181(1-2):33-7.

Liu C, Blumhardt LD. Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis. Mult Scler 2002;8(1):10-4.

Livesley E. Effects of electrical neuromuscular stimulation on functional performance in patients with multiple sclerosis. Physiotherapy 1992;78(12):914-7.

Mendoza RJ, Pittenger DJ, Weinstein CS. Unit management of depression of patients with multiple sclerosis using cognitive remediation strategies: a preliminary study. Neurorehab Neural Repair 2001;15(1):9-14.

Milanese C, La Mantia L, Salmaggi A, et al. Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results. Ital J Neurol Sci 1988;9(1):53-7.

Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244(3):153-9.

Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000;57(9):1319-24.

Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69(6):942-9.

Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol 2000;68(2):356-61.

Mondrup K, Pedersen E. The effect of the GABA-agonist, progabide, on stretch and flexor reflexes and on voluntary power in spastic patients. Acta Neurol Scand 1984a;69(4):191-9.

Mondrup K, Pedersen E. The clinical effect of the GABA-agonist, progabide, on spasticity. Acta Neurol Scand 1984b;69(4):200-6.

Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116 (Pt 1):135-46.

Mueller ME, Gruenthal M, Olson WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehab 1997;78(5):521-4.

Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990;27(6):591-605.

Newman PM, Nogues M, Newman PK, et al. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982;23(1):31-5.

Nielsen JF, Sinkjaer T, Jakobsen J. Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study. Mult Scler 1996;2(5):227-32.

Nortvedt MW, Riise T, Myhr KM, et al. Quality of life as a predictor for change in disability in MS. Neurology 2000;55(1):51-4.

Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56(11):1514-22.

O'Hara L, Cadbury H, De SL, et al. Evaluation of the effectiveness of professionally guided self-care for people with multiple sclerosis living in the community: a randomized controlled trial. Clin Rehab 2002;16(2):119-28.

Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997. Neurology 2001;57(12 Suppl 5):S36-45.

O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121 (Pt 3):495-503.

Ørsnes GB, Sørensen PS, Larsen TK, et al. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000;101(4):244-8.

Patten SB, Metz LM. Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001;7(4):243-8.

Patti F, Ciancio MR, Reggio E, et al. The impact of outpatient rehabilitation on quality of life in multiple sclerosis. J Neurol 2002;249(8):1027-33.

Patti F, L'Episcopo MR, Cataldi ML, et al. Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study. Acta Neurol Scand 1999;100(5):283-9.

Patzold U, Hecker H, Pocklington P. Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients. J Neurol Sci 1982;54(3):377-94.

Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. New Engl J Med 1989;320(23):1517-21.

Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996;39(4):432-41.

Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996;47(6):1463-8.

Pozzilli C, Brunetti M, Amicosante AM, et al. Home based management in multiple sclerosis: results of a randomised controlled trial. J Neurol Neurosurg Psych 2002;73(3):250-5.

Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehab 2003;17(1):42-7.

PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.[erratum appears in Lancet 1999 Feb 20;353(9153):678]. Lancet 1998;352(9139):1498-504.

Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991;41(5):692-6.

Rice GP. Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1989;16(4):451.

Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54(5):1145-55.

Rinne U. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Therapeutic Res

1980;28:827-36.

Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physic 1999;111(1):35-44.

Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001;7(6):354-8.

Rovaris M, Comi G, Ladkani D, et al. Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. Am J Neuroradiol 2003;24(1):75-81.

Rozin R, Schiff Y, Cooper G, et al. Vocational rehabilitation of multiple sclerosis (MS) patients. I. Analysis of clinical and demographic factors. Internat Rehab Med 1982;4(2):75-9.

Rozin R, Schiff Y, Kahana E, et al. Vocational status of multiple sclerosis patients in Israel. Arch Phys Med Rehab 1975;56(7):300-4.

Rudick RA, Breton D, Krall RL. The GABA-agonist progabide for spasticity in multiple sclerosis. Arch Neurol 1987;44(10):1033-6.

Rudick RA, Fisher E, Lee JC, et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000;6(6):365-72.

Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49(2):358-63.

Runmarker B, Andersson C, Odén A, et al. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994;241(10):597-604.

Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 1977;34(7):422-8.

Sastre-Garriga J, Tintoré M, Rovira A, et al. Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler 2003;9(1):39-43.

Sawa GM, Paty DW. The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979;6(3):351-4.

Scheinberg L, Holland N, Larocca N, et al. Multiple sclerosis; earning a living. NY State J Med 1980;80(9):1395-400.

Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. New Engl J Med 1985;312(23):1480-2.

Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psych 1990;147(11):1493-7.

Schmidt RT, Lee RH, Spehlmann R. Treatment of spasticity in multiple sclerosis: comparison of dantrolene sodium and diazepam. Trans Am Neurol Assoc 1975;100:235-7.

Schmidt RT, Lee RH, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psych 1976;39(4):350-6.

Schwartz CE, Coulthard-Morris L, Cole B, et al. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol 1997;54(12):1475-80.

Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344(8914):9-13.

Smith C, Birnbaum G, Carter JL, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994;44(11 Suppl 9):S34-42; discussion S42-3.

Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opinion 1981;7(6):374-83.

Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990;28(4):512-5.

Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999;52(1):57-62.

SPECTRIMS Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001;56(11):1496-504.

Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51(1):234-8.

Stien R, Nordal HJ, Oftedal SI, et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987;75(3):190-4.

Strasser-Fuchs S, Fazekas F, Deisenhammer F, et al. The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Mult Scler 2000;6 Suppl 2:S9-13.

Stuifbergen AK, Becker H, Blozis S, et al. A randomized clinical trial of a wellness intervention for women with multiple sclerosis. Arch Phys Med Rehab 2003;84(4):467-76.

Tintoré M, Rovira A, Río J, et al. New diagnostic criteria for multiple sclerosis - application in first demyelinating episode. Neurology 2003;60(1):27-30.

Trotter JL, Clifford DB, McInnis JE, et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 1989;25(2):172-8.

United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994;44(11 Suppl 9):S70-8.

Vahtera T, Haaranen M, Viramo-Koskela AL, et al. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehab 1997;11(3):211-9.

Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996;53(12):1270-5.

van de Wyngaert FA, Beguin C, D'Hooghe MB, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001;101(4):210-6.

Verdier-Taillefer MH, Sazdovitch V, Borgel F, et al. Occupational environment as risk factor for unemployment in multiple sclerosis. Acta Neurol Scand 1995;92(1):59-62.

Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002;59(4):555-9.

Wassem R, Dudley W. Symptom management and adjustment of patients with multiple sclerosis: a 4-year longitudinal intervention study. Clin Nurs Res 2003;12(1):102-17.

Weinshenker BG, Penman M, Bass B, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992;42(8):1468-71.

Weinstein A, Schwid SI, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56(3):319-24.

Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psych 2001;70(2):174-9.

Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26.

Zipoli V, Portaccio E, Siracusa G, et al. Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. Mult Scler 2003;9:481-5.